Insider Selling: Illumina (NASDAQ:ILMN) CAO Sells $58,141.92 in Stock

Illumina, Inc. (NASDAQ:ILMN) CAO Scott Ericksen sold 267 shares of Illumina stock in a transaction on Tuesday, November 10th. The shares were sold at an average price of $217.76, for a total value of $58,141.92. Following the completion of the transaction, the chief accounting officer directly owned 14,029 shares of the company’s stock, valued at $3,054,955.04. This represents a 1.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Price Performance

Shares of NASDAQ:ILMN traded down $2.54 during trading on Friday, reaching $207.01. 1,229,158 shares of the company traded hands, compared to its average volume of 2,291,458. The firm has a market capitalization of $31.30 billion, a PE ratio of 35.63, a PEG ratio of 2.84 and a beta of 1.46. Illumina, Inc. has a 52 week low of $112.65 and a 52 week high of $309.35. The company has a quick ratio of 2.05, a current ratio of 2.63 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $249.02 and its two-hundred day moving average is $179.64.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. Illumina’s revenue was up 4.2% on a year-over-year basis. During the same quarter last year, the business earned $1.34 earnings per share. As a group, sell-side analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current year.

Institutional Investors Weigh In On Illumina

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Illumina in the second quarter valued at approximately $3,374,423,000. WCM Investment Management LLC increased its holdings in shares of Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock worth $715,579,000 after buying an additional 1,851,848 shares in the last quarter. Primecap Management Co. CA acquired a new position in shares of Illumina during the second quarter worth $617,981,000. Janus Henderson Group PLC lifted its stake in shares of Illumina by 1.4% in the 1st quarter. Janus Henderson Group PLC now owns 2,100,638 shares of the life sciences company’s stock valued at $258,924,000 after acquiring an additional 29,094 shares during the last quarter. Finally, Southpoint Capital Advisors LP lifted its stake in shares of Illumina by 20.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,100,000 shares of the life sciences company’s stock valued at $258,846,000 after acquiring an additional 349,536 shares during the last quarter. 89.42% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on ILMN. UBS Group raised shares of Illumina from a “neutral” rating to a “buy” rating and raised their target price for the company from $135.00 to $260.00 in a report on Wednesday, September 9th. Piper Sandler boosted their target price on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Stifel Nicolaus upped their price target on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a report on Friday, July 31st. JPMorgan Chase & Co. reduced their price target on shares of Illumina from $320.00 to $300.00 and set an “overweight” rating on the stock in a research report on Friday, October 30th. Finally, TD Cowen increased their price target on shares of Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a research report on Tuesday, October 13th. Ten analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $244.24.

Key Stories Impacting Illumina

Investors following ILMN have been watching these stories:

• Positive Sentiment: An updated valuation estimate raised Illumina’s fair value to $261.45 per share from $248.90, offering a potential upside reference. Illumina Stock Sees Modest Fair Value Lift
• Neutral Sentiment: Analyst views remain divided, with ratings ranging from Sell to Buy. The reported consensus target is $244.24, while estimates reflect competing expectations for clinical demand and AI-related opportunities versus execution and valuation risks. Analyst Debate on Illumina’s Growth Outlook
• Neutral Sentiment: Chief Accounting Officer Scott Ericksen sold 267 shares under a pre-arranged Rule 10b5-1 plan, a relatively small reduction in his holdings. SEC filing

Illumina Company Profile

Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.